Clinical Practice Considerations for Androgen Deprivation Therapy
September 16th 2016Given the advancement in both pathophysiology and precision-guided approaches for prostate cancer, we assembled a panel of expert urologists to discuss clinically important aspects of ADT that will assist busy clinician decision makers in their optimization of outcomes for their advanced prostate cancer population.
AACU conference assembles 'urology advocacy armada'
September 6th 2016Facing uncertainty in Medicare and increasing regulatory and insurer burdens, the leaders of organizations representing urologists across the country gathered in mid-August for the 9th Annual AACU State Society Network Advocacy Conference.
Prostate Ca: Novel model predicts ‘true cancer state’
September 1st 2016Although various calculators are available for predicting biopsy results in men with prostate cancer being managed by active surveillance, a novel model developed by researchers at Johns Hopkins University is unique for its ability to predict a patient’s “true cancer state”; ie, the Gleason score that would be assigned on whole-gland analysis after radical prostatectomy.
Negative mpMRI does not rule out significant PCa
September 1st 2016As interest in using multiparametric MRI as a diagnostic tool for prostate cancer increases, urologists should know that a negative mpMRI does not rule out significant prostate cancer, researchers advised at the AUA annual meeting in San Diego.
QoL prognostic in mCRPC patients on salvage therapy
September 1st 2016Clinical outcomes of men with metastatic castration-resistant prostate cancer treated with enzalutamide (XTANDI) after chemotherapy correlate with health-related quality of life both at treatment initiation and its change longitudinally, researchers reported at the American Society of Clinical Oncology annual meeting in Chicago.
Convective water vapor ablation successful at 2 years
September 1st 2016A treatment system that uses steam to ablate prostate tissue (Rezūm, NxThera, Inc.) can be considered as a first-line therapy for the treatment of lower urinary tract symptoms secondary to BPH, say investigators from a non-randomized multicenter pilot study with 2-year duration of successful outcomes.
Offensive disclosure and defensive medicine: What you need to know
September 1st 2016The literature is rife with information and data, sometimes conflicting, as to whether disclosure and defensive medicine are beneficial to reducing liability and the chances of a lawsuit. One reason for this conflicting data is that the health care system as a whole is in the midst of a massive change, going from an authoritative physician model to one in which patients are increasingly engaged in their own medical care and treatment decisions.
AUA, others continue blitz on USPSTF reform
September 1st 2016The AUA and other organizations have been urging Congress to create transparency and accountability within the USPSTF while adding input and feedback from patients and specialists involved in treating the conditions for which it is developing recommendations.
Readers react to blog post about transgender community
August 30th 2016The recent blog post, “The transgender community: Urology has a role and a responsibility,” by Henry Rosevear, MD, prompted comments from several readers. Given the interest in this topic, Urology Times has compiled these comments.